Alpharma Seeks To Remove Stay On Generic Neurontin Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Company would launch gabapentin capsules "at risk" if stay on approval were lifted. The stay has been imposed because of dispute with Apotex regarding first-to-file exclusivity.
You may also be interested in...
Purepac Free To Launch Neurontin Generic After Court Lifts Stay
The company is not commenting on launch plans but previously said it would "commence commercial sales" if a court stay was lifted. Purepac said it would book revenues from its own gabapentin generic upon launch, but revenues received under an agreement with Teva would not be recorded until patent litigation with Pfizer is resolved.
Purepac Free To Launch Neurontin Generic After Court Lifts Stay
The company is not commenting on launch plans but previously said it would "commence commercial sales" if a court stay was lifted. Purepac said it would book revenues from its own gabapentin generic upon launch, but revenues received under an agreement with Teva would not be recorded until patent litigation with Pfizer is resolved.
Pfizer's Lyrica: "Approvable" For Three Indications, But Not Generalized Anxiety
The company received a "non-approvable" letter for the treatment of generalized anxiety disorder. Pfizer says it is working with FDA to resolve "open issues on all indications" for the Neurontin follow-on agent.